| |
| |
|
| Insider
Information: |
Formela Jean Francois |
| Relationship: |
|
| City: |
Waltham |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
13 |
|
| Direct
Shares |
7,291 |
|
|
Indirect Shares
|
24,762,873 |
|
|
| Direct
Value |
$155,882 |
|
|
|
Indirect Value
|
$272,924,216 |
|
|
| Total
Shares |
24,770,164 |
|
|
| Total
Value |
$273,080,098 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
4
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 179.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Decode Genetics Inc |
DCGN |
Director |
2003-09-09 |
0 |
2003-12-11 |
0 |
Premium* |
|
|
Exelixis Inc |
EXEL |
Director |
2003-11-13 |
0 |
2005-09-07 |
584,519 |
Premium* |
|
|
Nxstage Medical, Inc. |
NXTM |
Director, 10% Owner |
|
0 |
2006-05-26 |
2,592,126 |
Premium* |
|
|
Sgx Pharmaceuticals, Inc. |
SGXP |
Director, 10% Owner |
2006-02-01 |
0 |
2006-02-06 |
2,485,068 |
Premium* |
|
|
Achillion Pharmaceuticals Inc |
ACHN |
Director, 10% Owner |
2006-10-31 |
0 |
2006-10-31 |
1,968,670 |
Premium* |
|
|
Nuvelo Inc |
ABIO |
Director, 10% Owner |
|
0 |
2012-10-22 |
1,579,542 |
Premium* |
|
|
Horizon Pharma, Inc. |
HZNP |
Director, 10% Owner |
|
0 |
2011-08-02 |
5,393,178 |
Premium* |
|
|
Egalet Corp |
EGLT |
Director, 10% Owner |
|
0 |
2014-02-11 |
2,460,949 |
Premium* |
|
|
Intellia Therapeutics, Inc. |
NTLA |
Director |
2022-06-14 |
7,291 |
2021-06-28 |
10,000 |
Premium* |
|
|
Spero Therapeutics Inc |
SPRO |
Director |
2017-11-06 |
0 |
2017-11-06 |
2,408,128 |
Premium* |
|
|
Translate Bio, Inc. |
TBIO |
Director |
2018-07-02 |
0 |
2021-09-14 |
0 |
Premium* |
|
|
Ikena Oncology, Inc. |
IKNA |
Director |
|
0 |
2021-12-14 |
4,143,544 |
Premium* |
|
|
Korro Bio |
KRRO |
|
2023-11-03 |
0 |
2024-04-22 |
1,137,149 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
96 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NXTM |
Nxstage Medical, Inc. |
Director |
– • • |
2006-05-26 |
4 |
OE |
$7.13 |
$74,394 |
I/I |
10,434 |
2,592,126 |
|
- |
|
| ACHN |
Achillion Pharmaceuticals... |
Director |
– • • |
2006-10-31 |
4 |
A |
$0.00 |
$0 |
I/I |
1,968,670 |
1,968,670 |
0 |
- |
|
| ABIO |
Nuvelo Inc |
Director |
– • – |
2010-03-29 |
4 |
S |
$7.56 |
$1,058,400 |
I/I |
(140,000) |
1,337,612 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
Director |
– • • |
2011-08-02 |
4 |
B |
$9.00 |
$3,328,326 |
I/I |
369,814 |
2,533,327 |
2.25 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
Director |
– • • |
2011-08-02 |
4 |
A |
$0.00 |
$3,653,586 |
I/I |
2,163,513 |
2,163,513 |
0 |
- |
|
| ABIO |
Nuvelo Inc |
Director |
– • • |
2012-10-22 |
4 |
A |
$0.39 |
$125,016 |
I/I |
317,379 |
1,579,542 |
0 |
- |
|
| EGLT |
Egalet Corp |
Director |
– • • |
2014-02-11 |
4 |
B |
$12.00 |
$500,004 |
I/I |
41,667 |
2,152,222 |
2.25 |
- |
|
| EGLT |
Egalet Corp |
Director |
– • • |
2014-02-11 |
4 |
A |
$0.00 |
$2,302,218 |
I/I |
2,080,555 |
2,110,555 |
0 |
- |
|
| EGLT |
Egalet Corp |
Director |
– • • |
2014-02-11 |
4 |
OE |
$0.00 |
$30 |
I/I |
30,000 |
1,726,852 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
I/I |
4,429,788 |
4,429,788 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2017-03-09 |
4 |
S |
$13.85 |
$216,432 |
I/I |
(15,628) |
5,504 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2017-03-10 |
4 |
S |
$14.06 |
$77,410 |
I/I |
(5,504) |
0 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2017-07-07 |
4 |
S |
$16.77 |
$502,992 |
I/I |
(30,000) |
3,699,788 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2017-07-10 |
4 |
S |
$16.17 |
$646,888 |
I/I |
(40,000) |
3,659,788 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2017-07-11 |
4 |
S |
$16.07 |
$1,285,560 |
I/I |
(80,000) |
3,579,788 |
0 |
- |
|
| SPRO |
Spero Therapeutics Inc |
Director |
– • – |
2017-11-06 |
4 |
B |
$14.00 |
$5,999,994 |
I/I |
428,571 |
2,408,128 |
2.1 |
- |
|
| SPRO |
Spero Therapeutics Inc |
Director |
– • – |
2017-11-06 |
4 |
A |
$0.00 |
$0 |
I/I |
1,936,776 |
1,979,557 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2018-03-20 |
4 |
S |
$23.78 |
$936,743 |
I/I |
(39,245) |
0 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2018-05-16 |
4 |
AS |
$25.04 |
$167,389 |
I/I |
(6,686) |
0 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2018-06-19 |
4 |
AS |
$27.84 |
$186,908 |
I/I |
(6,686) |
0 |
0 |
- |
|
| TBIO |
Translate Bio, Inc. |
Director |
– • – |
2018-07-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,832,010 |
3,922,010 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2018-07-16 |
4 |
AS |
$30.97 |
$208,397 |
I/I |
(6,686) |
0 |
0 |
- |
|
| TBIO |
Translate Bio, Inc. |
Director |
– • – |
2020-08-25 |
4 |
S |
$15.00 |
$516,160 |
I/I |
(34,410) |
3,887,600 |
0 |
% |
|
| TBIO |
Translate Bio, Inc. |
Director |
– • – |
2020-08-26 |
4 |
S |
$14.80 |
$656,746 |
I/I |
(44,381) |
3,843,219 |
0 |
% |
|
| TBIO |
Translate Bio, Inc. |
Director |
– • – |
2020-08-27 |
4 |
S |
$14.38 |
$145,217 |
I/I |
(10,097) |
3,833,122 |
0 |
% |
|
96 Records found
|
|
Page 3 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
